Transthoracic Echocardiography in COVID 19 Registry

Please make sure you enter the data after each scan completion in a confirmed or high-probability Covid-19+ patient. Thank you for your contribution and do not forget to bookmark this link.

Our objective is to capture this information quickly and efficiently in real time following echocardiographic examinations and to therefore gain a better picture of the cardiac manifestations of COVID-19 and the contribution of these to patient mortality and morbidity.

Before we begin, may we just remind you of our Code of Conduct for ESC surveys?
Your participation is anonymous. We will not disclose your identity to any third party.
We comply with the European General Data Protection Regulation (GDPR) 2016/679. Any personal data processed in connection with this survey will be treated confidentially and only used by the ESC for the purposes of market research and not for promotion. Survey results will be kept for a minimum of 24 months for analysis and quality control purposes. We take all reasonable care to prevent any unauthorized access to your personal data. We respect your privacy and your right to access, modify, or suppress your personal data. At any time, you can ask to know what personal data is being held. If you have any questions about data protection or require further information, please contact our data protection officer (DPO) at dpo@escardio.org.
You have the right to end your participation in this survey at any time.

Question Title

* 1. Country where scan performed

Question Title

* 2. Where in the hospital did you perform the TTE scan? (single answer)

Intensive care unit

High dependency ward

Accident and Emergency Unit

Cath lab

Corona virus ward

Cardiology ward

Out-patient department

Other hospital ward (please specify)

Question Title

* 3. Patient age (enter a number)

Question Title

* 4. Patient gender

Male

Female

Question Title

* 5. Patient condition (select all that apply)

Known COVID-19 positive

High probability of COVID-19

Evidence of pneumonia

Question Title

* 6. Severity of symptoms (single answer)

Mild

Moderate

Severe

Question Title

* 7. Pre-existing cardiovascular co-morbidities (select all that apply)

Known heart failure

Known ischemic heart disease

Known valve disease

Hypertension

Diabetes Mellitus

Other (please specify)

Question Title

* 8. Indication for scan (select all that apply)

Suspected left sided heart failure

Suspected right heart failure

Chest pain and ST elevation on ECG (myocardial infarction vs myocarditis)

High troponin level

High BNP level

Ventricular arrythmias

Shock

Tamponade

Other (please specify)

Question Title

* 9. Left ventricular function (select all that apply)

Normal

Mildly impaired (ejection fraction 55-45%)

Moderately impaired (ejection fraction 35-45%)

Severely impaired (ejection fraction <35%)

Dilated left ventricle

Evidence of new myocardial infarction

Evidence of myocarditis

Evidence of likely tako-tsubo cardiomyopathy

Tamponade

Question Title

* 10. Right ventricular function (select all that apply)

Normal

Mild or moderate RV impairment

Severe RV impairment

RV dilatation

D-shaped left ventricle

Pulmonary hypertension

Question Title

* 11. Did your echo scan change management?

Yes

If so how?

Transthoracic Echocardiography in COVID 19 Registry

Question Title

* 1. Country where scan performed

Question Title

* 2. Where in the hospital did you perform the TTE scan? (single answer)

Question Title

* 3. Patient age (enter a number)

Question Title

* 4. Patient gender

Question Title

* 5. Patient condition (select all that apply)

Question Title

* 6. Severity of symptoms (single answer)

Question Title

* 7. Pre-existing cardiovascular co-morbidities (select all that apply)

Question Title

* 8. Indication for scan (select all that apply)

Question Title

* 9. Left ventricular function (select all that apply)

Question Title

* 10. Right ventricular function (select all that apply)

Question Title

* 11. Did your echo scan change management?

Question Title

* 12. Please share any other comments